{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:40:52Z","timestamp":1760301652402,"version":"build-2065373602"},"reference-count":24,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2009,1,6]],"date-time":"2009-01-06T00:00:00Z","timestamp":1231200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2009,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>High\u2010risk (HR) human papillomavirus (HPV) testing is standard practice for triaging women who have Papanicolaou (Pap) smears with atypical squamous cells of undetermined significance (ASC\u2010US), however, only 5% to 17% of these women have underlying cervical intraepithelial neoplasia 2 (CIN\u20102)\/CIN\u20103. Recent reports have demonstrated that the presence of either HPV type 16 (HPV\u201016) or HPV\u201018 confers an elevated risk for CIN\u20102\/CIN\u20103. The current study was designed to determine the prevalence of HPV\u201016 and HPV\u201018 in ASC\u2010US Pap smears and to determine whether further typing would enhance the risk stratification of patients for CIN\u20102\/CIN\u20103.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>One hundred seventy\u2010eight Pap smears with ASC\u2010US were screened retrospectively for HR HPV by using the proprietary Invader screening assay followed by typing for HPV\u201016 and HPV\u201018 by using Invader type\u2010specific probes on 100 of the samples. Clinical follow\u2010up results were correlated with HPV types.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Fifty\u2010one percent of the ASC\u2010US samples were positive for HR HPV, the majority of which (70%) harbored non\u2010HPV\u201016\/HPV\u201018 HR HPV types; 27% were associated with HPV\u201016, whereas only 3% contained HPV\u201018. The screening assay indicated that 46% of women who had Pap smears with ASC\u2010US were in need of further HPV\u201016\/HPV\u201018 typing. Testing for HPV\u201016 stratified women with ASC\u2010US into 3 groups: 1) 14% of women were positive for HPV\u201016 and had a high risk (54%) of CIN\u20102\/CIN\u20103 on follow\u2010up biopsy, 2) 35% of women were positive for non\u2010HPV\u201016 HPV types and had an intermediate risk (9%), and 3) 51% of women were negative for HPV and had a negligible risk for CIN\u20102\/CIN\u20103.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>The combined application of a proprietary screening assay and a type\u2010specific HPV\u201016 assay demonstrated global potential for the development of tailored management protocols for women who have Pap smears with ASC\u2010US. Cancer 2009. \u00a9 2009 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.24091","type":"journal-article","created":{"date-parts":[[2009,2,2]],"date-time":"2009-02-02T13:26:20Z","timestamp":1233581180000},"page":"823-832","source":"Crossref","is-referenced-by-count":11,"title":["Invader human papillomavirus (HPV) type 16 and 18 assays as adjuncts to HPV screening of cervical papanicolaou smears with atypical squamous cells of undetermined significance"],"prefix":"10.1002","volume":"115","author":[{"given":"Anna K.","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond C.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Stephen","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shikha","family":"Bose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,1,6]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa071430"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21955"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000109426.82624.f8"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021641"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2007.07.050"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2007.07.047"},{"key":"e_1_2_6_9_2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/jnci\/93.4.293","article-title":"Comparison of 3 management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial","volume":"93","author":"Solomon D","year":"2001","journal-title":"J Natl Cancer Inst."},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600688"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61416-0"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji187"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji186"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1086\/507909"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603843"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21664"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01424-07"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01824-07"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.5858\/2004-128-1224-BIARRP"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.36.10.3020-3027.1998"},{"key":"e_1_2_6_21_2","unstructured":"Quantitative Skills Consultancy for Research and Statistics. Simple Interactive Biostatistical Analysis. Biostatistics tools. Available at:http:\/\/www.quantitativeskills.com\/sisa\/. Accessed June 1 2008."},{"key":"e_1_2_6_22_2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.6004\/jnccn.2008.0008","article-title":"The potential utility of HPV genotyping in screening and clinical management","volume":"6","author":"Castle PE","year":"2008","journal-title":"J Natl Compr Canc Netw."},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2008.93"},{"key":"e_1_2_6_24_2","first-page":"645","article-title":"ACOG Practice Bulletin number 66, September 2005: management of abnormal cervical cytology and histology","volume":"106","author":"American College of Obstetricians and Gynecologists","year":"2005","journal-title":"Obstet Gynecol."},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.16.2120"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.24091","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.24091","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:03:33Z","timestamp":1760299413000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.24091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,6]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,2,15]]}},"alternative-id":["10.1002\/cncr.24091"],"URL":"https:\/\/doi.org\/10.1002\/cncr.24091","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2009,1,6]]}}}